Dosimertinib

Dosimertinib

• CAS Number: 2403760-70-1
• UNSPSC Description: Dosimertinib-d3-d3 is a potent and orally active EGFR inhibitor. Dosimertinib-d3-d3 decreases the expression of p-EGFR and p-ERK protein levels. Dosimertinib-d3-d3 shows antiproliferative and anti-tumor activity. Dosimertinib-d3-d3 has the potential for the research of non-small-cell lung cancer (NSCLC)[1].
• Target Antigen: EGFR; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: JAK/STAT Signaling;Others;Protein Tyrosine Kinase/RTK
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Solubility: 10 mM in DMSO
• Smiles: [2H]/C([2H])=C\C(NC1=CC(NC2=NC=CC(C3=CN(C4=C3C=CC=C4)C([2H])([2H])[2H])=N2)=C(C=C1N(CCN(C)C)C)OC)=O
• Molecular Weight: 504.64
• References & Citations: [1]Chen C, et al. Cyclization strategy leads to highly potent Bromodomain and extra-terminal (BET) Bromodomain inhibitors for the treatment of acute liver injury. Eur J Med Chem. 2022 Dec 16;247:115023.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported